NBIX - Neurocrine gains after Phase 3 win for genetic disorder drug
2023-09-12 11:57:12 ET
More on Neurocrine
- Seeking Alpha’s Quant Rating on Neurocrine Biosciences
- Historical earnings data for Neurocrine Biosciences
- Financial information for Neurocrine Biosciences
- Neurocrine Needs A Meaningful Clinical Win To Break Out, And Crinecerfont Could Do It
- Neurocrine Biosciences: Ingrezza Impresses Amid Costly Pipeline Expansion Efforts
- Neurocrine Biosciences, Inc. 2023 Q2 - Results - Earnings Call Presentation
- Neurocrine Biosciences, Inc. ( NBIX ) Q2 2023 Earnings Call Transcript
- Neurocrine releases new data on Ingrezza for Huntington's disease chorea
- Neurocrine nabs FDA label expansion for Ingrezza
- BMO upgrades Neurocrine to market perform on Ingrezza outlook
For further details see:
Neurocrine gains after Phase 3 win for genetic disorder drug